"NIH Funds First Artificial Pancreas Trial For Pregnant Women With Type 1 Diabetes In The U.S."
The National Institutes of Health has awarded a R01 grant to a multi-institutional team to develop and evaluate a pregnancy-specific Artificial Pancreas in a sequence of in-clinic and transitional environment clinical trials. The researchers hope that the first-in-the-nation studies will lead to a safe and effective at-home clinical trial with an extension phase to the end of pregnancy. The project brings together the experienced engineering team of the Harvard John A. Paulson School of Engineering and Applied Sciences and a clinical research consortium made up of specialists from the Icahn School of Medicine at Mount Sinai, the Mayo Clinic, and the Sansum Diabetes Research Institute. "Achieving and maintaining the very narrow range blood glucose levels required for the best fetal outcomes for pregnant women with type 1 diabetes is extremely challenging, even with optimal clinical care," said Carol Levy, MD, CDE, clinical director of the Mount Sinai Diabetes Center. "The use of customized technology provides an important opportunity to improve patient and fetal outcomes. We are excited to be part of the team evaluating this important area of research designed to improve care and reduce patient burden."
— Carol J. Levy, MD, Clinical Director, Mount Sinai Diabetes Center, Associate Professor, Medicine, Endocrinology, Diabetes, Bone Disease, Icahn School of Medicine at Mount Sinai
Additional coverage: PharmiWeb; Diabetes.co.uk